Ads
related to: camp4 therapeutics corp ipo schedule
Search results
Results From The WOW.Com Content Network
CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and ...
An initial public offering (IPO) or stock launch is a public offering in which shares of a company are sold to institutional investors [1] and usually also to retail (individual) investors. [2] An IPO is typically underwritten by one or more investment banks , who also arrange for the shares to be listed on one or more stock exchanges .
CRISPR Therapeutics recently hit a breakthrough point when it earned approval for its first product, Casgevy, a therapy for sickle cell disease and transfusion-dependent beta-thalassemia.
Some 108 companies conducted their IPO in 2023 and raised $19.4 billion, according to Renaissance Capital. Those figures rose markedly from the 2022 doldrums of 71 IPOs and just $7.7 billion raised.
S&P MidCap 400 constituent LKQ Corp. (NASD:LKQ) will replace Airgas Inc. (NYSE:ARG) in the S&P 500. Air Liquide SA acquired Airgas. [256] May 12, 2016: TXRH: Texas Roadhouse: ALK: Alaska Air Group: S&P 500 constituent Western Digital Corp. (NASD:WDC) is acquiring SanDisk Corp. in a deal expected to be completed on or about that date pending ...
In May 2014, Kite Pharma filed a registration with the SEC for an initial public offering (IPO) of its common stock. [45] In June 2014, Kite Pharma sold 8,625,000 shares of its common stock in their IPO at $17.00 per share, for gross proceeds of $146.6 million. [46] [47] [48] The company listed on the NASDAQ Global market under the symbol ...
The U.S. IPO market is staging a strong comeback after two dismal years, thanks to a rally in the stock market and growing optimism of a possible interest rate cut this year. Rapport, backed by ...
The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018, Juno Therapeutics was acquired by biotechnology company Celgene for $9 billion. [2] In November 2019, Bristol-Myers Squibb (BMS) announced that it has completed its acquisition of Celgene. [3]